Its research portfolio comprises two primary areas, DNA/RNA medicines, which include drugs that are based on chemical modifications of oligonucleotides; and small molecules.
The company’s lead product from the DNA/RNA medicines program is Genasense, which completed phase 3 trials in combination with chemotherapy in the treatment of malignant melanoma, chronic lymphocytic leukemia, multiple myeloma, nonsmall cell lung cancer, small cell lung cancer, and prostate cancer.
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is designed to block chemotherapy-induced apoptosis.
Its lead product from small molecule program is Ganite, which is used for treatment of cancer-related hypercalcemia that is resistant to hydration.
Genta’s preclinical pipeline includes research programs in antisense, RNA interference, and decoys.
In addition, the company is evaluating oral formulations of gallium-containing compounds.
Genta was founded in 1988 and is based in Berkeley Heights, New Jersey.
